Literature DB >> 24612478

Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on sexual function in postmenopausal women: a randomized controlled trial.

Tatiane Fernandes1, Lucia Helena Costa-Paiva, Aarão Mendes Pinto-Neto.   

Abstract

INTRODUCTION: Female libido is multifactorial and complex. Declining estrogen levels in postmenopausal women affects vaginal function. AIM: The aim of this study was to evaluate female sexual function after using topical estrogen, testosterone, or polyacrylic acid as vaginal lubricants with K-Y jelly as a placebo lubricant.
METHODS: This was a randomized controlled clinical trial on 80 postmenopausal women between 40 and 70 years of age with follow-up at the Menopause Clinic of the CAISM Unicamp. The women were randomized to treatment with topical vaginal estrogen, testosterone, polyacrylic acid, or oil lubricant alone, three times a week for a period of 12 weeks from November 2011 to January 2013. MAIN OUTCOME MEASURE: We used the Female Sexual Function Index (FSFI) to assess changes in sexual response at baseline, and after 6 and 12 weeks.
RESULTS: After 12 weeks of treatment, polyacrylic acid and topical testosterone produced improvements in the FSFI domains of sexual desire, lubrication, satisfaction, reduced pain during intercourse, and total score compared with lubricant alone. Treatment with topical estrogen in comparison with lubricant alone showed an improvement in the FSFI field of desire. The intragroup analysis over the time of the treatment showed improvements in the fields of desire, lubrication, and reduced pain for polyacrylic acid, testosterone, and estrogen. Furthermore, women who used testosterone showed improvements over time in the fields of arousal, orgasm, and satisfaction.
CONCLUSIONS: Treatment of postmenopausal women with symptoms of vaginal atrophy with polyacrylic acid, testosterone, and estrogen for 12 weeks produced improvements in self-reported female sexual function when compared with a placebo lubricant.
© 2014 International Society for Sexual Medicine.

Entities:  

Keywords:  Hormones; Sexuality; Vaginal Atrophy

Mesh:

Substances:

Year:  2014        PMID: 24612478     DOI: 10.1111/jsm.12473

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  6 in total

Review 1.  Treating menopause - MHT and beyond.

Authors:  Susan R Davis; Rodney J Baber
Journal:  Nat Rev Endocrinol       Date:  2022-05-27       Impact factor: 47.564

2.  Female sexual function after transobturator tape in women with urodynamic stress urinary incontinence.

Authors:  Abdulmuttalip Simsek; Faruk Ozgor; Bahar Yuksel; Onur Kucuktopcu; Sinan Levent Kirecci; Mehmet Toptas; Omer Sarılar; Ahmet Yalcin Berberoglu; Zafer Gokhan Gurbuz; Saban Mimaroglu; Fatih Akbulut; Murat Baykal; Burak Arslan; Metin Savun; Burak Ucpinar
Journal:  Springerplus       Date:  2014-09-30

3.  Improvements to the Vulva, Vestibule, Urethral Meatus, and Vagina in Women Treated With Ospemifene for Moderate to Severe Dyspareunia: A Prospective Vulvoscopic Pilot Study.

Authors:  Sue W Goldstein; Ashley G Winter; Irwin Goldstein
Journal:  Sex Med       Date:  2018-04-18       Impact factor: 2.491

4.  Description of Vaginal Laxity and Prolapse and Correlation With Sexual Function (DeVeLoPS).

Authors:  Allison Polland; Vi Duong; Rachel Furuya; Jocelyn J Fitzgerald; Haijun Wang; Aya Iwamoto; Sarah Bradley; Cheryl B Iglesia
Journal:  Sex Med       Date:  2021-10-08       Impact factor: 2.491

Review 5.  Local oestrogen for vaginal atrophy in postmenopausal women.

Authors:  Anne Lethaby; Reuben Olugbenga Ayeleke; Helen Roberts
Journal:  Cochrane Database Syst Rev       Date:  2016-08-31

6.  Ospemifene May Not Treat Vulvar Atrophy: A Report of Two Cases.

Authors:  Andrew T Goldstein; Michelle A King
Journal:  Sex Med       Date:  2016-06-29       Impact factor: 2.491

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.